Article
Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.
Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Cancer (impact factor:
4.77).
09/2011;
118(9):2532-40.
DOI:10.1002/cncr.26516
pp.2532-40
Source: PubMed
-
Citations (0)
- Cited In (1)
-
Article: Evidence-Based Guidelines for Precision Risk Stratifica- tion-Based Screening (PRSBS) for Colorectal Cancer: Lessons Learned from the US Armed Forces: Consensus and Future Directions
[show abstract] [hide abstract]
ABSTRACT: Colorectal cancer (CRC) is the third most common cause of cancer-related death in the United States (U.S.), with estimates of 143,460 new cases and 51,690 deaths for the year 2012. Numerous organizations have published guidelines for CRC screening; however, these numerical estimates of incidence and disease-specific mortality have remained stable from years prior. Technological, genetic profiling, molecular and surgical advances in our modern era should allow us to improve risk stratification of patients with CRC and identify those who may benefit from preventive measures, early aggressive treatment, alternative treatment strategies, and/or frequent surveillance for the early detection of disease recurrence. To better negotiate future economic constraints and enhance patient outcomes, ultimately, we propose to apply the principals of personalized and precise cancer care to risk-stratify patients for CRC screening (Precision Risk Stratification- Based Screening, PRSBS). We believe that genetic, molecular, ethnic and socioeconomic disparities impact oncological outcomes in general, those related to CRC, in particular. This document highlights evidence-based screening recommendations and risk stratification methods in response to our CRC working group private-public consensus meeting held in March 2012. Our aim was to address how we could improve CRC risk stratification-based screening, and to provide a vision for the future to achieving superior survival rates for patients diagnosed with CRC.Journal of Cancer. 02/2013; 4:172-192.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
282 prospectively
95% confidence interval [CI]
harbor levels
highest recurrence risk
individual lymph nodes
lymph node-negative
lymph nodes
metastatic colorectal cancer cells
multivariate polytomous logistic regression
occult metastases undetected
Occult tumor burden
pN0 colorectal cancer patients
pN0 patients
primary outcome measure
racial differences
recurrence rate [RR]
regional lymph nodes
risk category
stage-specific outcomes
whites exhibited 4-fold greater occult metastases